Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD320 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD320 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD320 Products |
| Gene Delivery | CD320 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based internalization assays. |
View CD320 Products |
| Benchmark Ab | Anti-CD320 Recombinant Antibody Recombinant positive control derived from published benchmark sequences for validation. |
View CD320 Products |
| Validator | CD320 siRNA Set For knockdown verification in target-specificity and functional assays. |
View CD320 Products |
| Related Target A | TCN2 (Transcobalamin 2) The natural ligand of CD320. Essential for competitive binding and ligand-blocking assay development. |
View TCN2 Products |
| Related Target B | TFRC (CD71 / Transferrin Receptor) Synergistic nutrient uptake receptor co-upregulated in rapidly proliferating tumor cells. |
View TFRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily off-target counter-screening | LDLR-like domain-containing family proteins strictly verified by mass spectrometry to avoid cross-reactivity. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included to establish assay baseline. |
| False Positives | Sequence-verified siRNA included for target knockdown and specificity validation. |
Live CD320 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD320 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD320's rapid internalization pathway to deliver cytotoxic or therapeutic payloads directly into vitamin B12-dependent tumor cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech startups, Academic consortia | Solid Tumors (Ovarian, Breast, Colon) | Internalization Assay (Need high-purity ECD-Fc and stable cell lines) |
| Blocking Monoclonal Antibody | Oncology research institutes | B12-deprivation cancer therapy | Ligand-competition assays (Need biologically relevant CD320 and TCN2 proteins) |
| Targeted Radiopharmaceuticals | Nuclear medicine developers | Metastatic tumors, Diagnostic imaging | High-affinity screening (Need sequence-verified, natively folded target proteins) |